Zobrazeno 1 - 10
of 49
pro vyhledávání: '"Sanna Maria Käkönen"'
Autor:
Sanna-Maria Käkönen, Olli Kallioniemi, Theresa A. Guise, Merja Perälä, Anne Marjamäki, Marjo Pihlavisto, Liisa Nissinen, Anni Wärri, Jussi M. Halleen, Jukka P. Rissanen, Khalid S. Mohammad, Rami S. Käkönen, Sirkku Pollari
PDF file - 25K, Supplementary Figure 1. Basal and TGF-b-induced IL-11 production in parental MDA-MB-231 and highly metastatic MDA-MB-231(SA) cells. ***, P < 0.001 (t test).
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::05dd2a64fe7c78aed6c271fc0f360909
https://doi.org/10.1158/1541-7786.22517794
https://doi.org/10.1158/1541-7786.22517794
Autor:
Sanna-Maria Käkönen, Olli Kallioniemi, Theresa A. Guise, Merja Perälä, Anne Marjamäki, Marjo Pihlavisto, Liisa Nissinen, Anni Wärri, Jussi M. Halleen, Jukka P. Rissanen, Khalid S. Mohammad, Rami S. Käkönen, Sirkku Pollari
PDF file - 28K, Supplementary Figure 2. A, the effects of the six most potent siRNA screen hits on IL-11 secretion in MDA-MB-231(SA) cells (n=3). B, the effects of heparan sulfate modifying enzymes on IL-11 secretion in MDA-MB-231(SA) cells (n=4). *,
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0cc8ee4958bd7f4ba9bd0cdbdd6c3b27
https://doi.org/10.1158/1541-7786.22517791.v1
https://doi.org/10.1158/1541-7786.22517791.v1
Autor:
Sanna-Maria Käkönen, Olli Kallioniemi, Theresa A. Guise, Merja Perälä, Anne Marjamäki, Marjo Pihlavisto, Liisa Nissinen, Anni Wärri, Jussi M. Halleen, Jukka P. Rissanen, Khalid S. Mohammad, Rami S. Käkönen, Sirkku Pollari
XLS file - 49K, Supplementary Table 2. Effects of 196 siRNAs (including 2 siRNAs targeting IL11) on TGF-�-induced IL-11 production in MDA-MB-231(SA) cells. The relative IL-11 concentration values were obtained by dividing the IL-11 concentration by
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5b709dac8dfe314987926659a60d2c61
https://doi.org/10.1158/1541-7786.22517782
https://doi.org/10.1158/1541-7786.22517782
Autor:
Sanna-Maria Käkönen, Olli Kallioniemi, Theresa A. Guise, Merja Perälä, Anne Marjamäki, Marjo Pihlavisto, Liisa Nissinen, Anni Wärri, Jussi M. Halleen, Jukka P. Rissanen, Khalid S. Mohammad, Rami S. Käkönen, Sirkku Pollari
TGF-β regulates several steps in cancer metastasis, including the establishment of bone metastatic lesions. TGF-β is released from bone during osteoclastic bone resorption and it stimulates breast cancer cells to produce osteolytic factors such as
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a96373f0bdeb900580a415b881a50d96
https://doi.org/10.1158/1541-7786.c.6541825.v1
https://doi.org/10.1158/1541-7786.c.6541825.v1
Autor:
Sanna-Maria Käkönen, Olli Kallioniemi, Theresa A. Guise, Merja Perälä, Anne Marjamäki, Marjo Pihlavisto, Liisa Nissinen, Anni Wärri, Jussi M. Halleen, Jukka P. Rissanen, Khalid S. Mohammad, Rami S. Käkönen, Sirkku Pollari
PDF file - 6K, Supplementary Table 1. Primers and probes used for quantitative RT-PCR.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::34cbd2c76aa77739df402da43a353e2e
https://doi.org/10.1158/1541-7786.22517785.v1
https://doi.org/10.1158/1541-7786.22517785.v1
Autor:
Sanna-Maria Käkönen, Olli Kallioniemi, Theresa A. Guise, Merja Perälä, Anne Marjamäki, Marjo Pihlavisto, Liisa Nissinen, Anni Wärri, Jussi M. Halleen, Jukka P. Rissanen, Khalid S. Mohammad, Rami S. Käkönen, Sirkku Pollari
PDF file - 38K, Supplementary Figure 3. A, expression of HS6ST2 mRNA in MDA-MB-231(SA) versus parental MDA-MB-231 cells. B, validation of the knockdown efficacies of siRNAs by quantitative RT-PCR.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d0db584fe32f7f2ad70f7ab80f7a4cae
https://doi.org/10.1158/1541-7786.22517788.v1
https://doi.org/10.1158/1541-7786.22517788.v1
Autor:
Arne Scholz, Robert L. Vessella, Jussi M. Halleen, Sanna-Maria Käkönen, Karl Ziegelbauer, Dominik Mumberg, Eva Corey, Salla K. Laine, Esa J. Alhoniemi, ZhiQi Peng, Jukka P. Morko, Yvonne M. Konkol, Jukka P. Rissanen, Katja M. Fagerlund, Mari I. Suominen
'Supplementary Figure S1 shows the efficacy of radium-223 in an abiraterone-resistant LuCaP 58 prostate cancer PDX model; Supplementary Table S1 shows the characteristics of LNCaP and LuCaP 58 prostate cancer growth in bone models in mice and respons
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8eefdff0b26f025fb6a72322e6c00e75
https://doi.org/10.1158/1078-0432.22467708.v1
https://doi.org/10.1158/1078-0432.22467708.v1
Autor:
Arne Scholz, Matias Knuuttila, Justyna Zdrojewska, Mari I. Suominen, Esa Alhoniemi, Christoph A. Schatz, Sabine Zitzmann-Kolbe, Sanna-Maria Käkönen, Urs B. Hagemann
Publikováno v:
Cancer Research. 83:5043-5043
Radium-223, a bone-specific alpha particle therapy, increased survival of patients with metastatic castration-resistant prostate cancer (mCRPC) and bone metastases (Parker et al., NEJM 2013) 177Lu-PSMA-617 is a small molecule radioligand that deliver
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::240ddf76171c8f60a96918c9101205e2
https://doi.org/10.1158/1538-7445.am2023-5043
https://doi.org/10.1158/1538-7445.am2023-5043
Autor:
Mari I. Suominen, Matias Knuuttila, Christoph A. Schatz, Andreas Schlicker, Jukka Vääräniemi, Birgitta Sjöholm, Esa Alhoniemi, Bernard Haendler, Dominik Mumberg, Sanna-Maria Käkönen, Arne Scholz
Publikováno v:
International Journal of Molecular Sciences
Volume 24
Issue 3
Pages: 2189
Volume 24
Issue 3
Pages: 2189
Radium-223 dichloride and enzalutamide are indicated for metastatic castration-resistant prostate cancer and their combination is currently being investigated in a large phase 3 clinical trial. Here, we evaluated the antitumor efficacy of radium-223,
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2effe77e6e20ca5f5d033c0b69400e3e
https://doi.org/10.3390/ijms24032189
https://doi.org/10.3390/ijms24032189
Autor:
Dominik Mumberg, Anniina Luostarinen, Mari I. Suominen, Jenni H. Mäki-Jouppila, Katja M. Fagerlund, Birgitta Sjöholm, Jukka P. Rissanen, Sanna-Maria Käkönen, Gerhard Siemeister, Arne Scholz, Anna Huhtinen, Esa Alhoniemi
Publikováno v:
International Journal of Molecular Sciences, Vol 22, Iss 5570, p 5570 (2021)
International Journal of Molecular Sciences
Volume 22
Issue 11
International Journal of Molecular Sciences
Volume 22
Issue 11
Osteolytic bone disease is a hallmark of multiple myeloma (MM) mediated by MM cell proliferation, increased osteoclast activity, and suppressed osteoblast function. The proteasome inhibitor bortezomib targets MM cells and improves bone health in MM p
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::bc64c584fab49eaba12f8fc70a0b90a4
https://www.mdpi.com/1422-0067/22/11/5570
https://www.mdpi.com/1422-0067/22/11/5570